Polypeptide combinations and uses thereof
OwnerSarah WILLinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination of polypeptides and uses thereof. In particular, the present invention relates to a combination of an amylin receptor agonist and a GLP-1 receptor agonist, and uses thereof.
Claims38
A method for treating and/or preventing a disease or disorder in a subject, the method comprising administering to the subject (a) an amylin receptor (AMYR) agonist, wherein the AMYR agonist has selectivity to AMYR as compared to a calcitonin receptor (CTR);
- and (b) a GLP-1 receptor (GLP-1R) agonist.
(canceled)
5-7. (canceled)
9-10. (canceled)
A method for treating and/or preventing a disease or disorder in a subject, the method comprising administering to the subject (a) a polypeptide, or pharmaceutically acceptable salt thereof, which is an AMYR agonist comprising an amino acid sequence having at least 90% identity to pramlintide (KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide, SEQ ID NO:
- 5);
- and (b) a GLP-1R agonist.
(canceled)
A method for treating a disease or disorder in a subject, the method comprising administering to the subject (a) an AMYR agonist;
- and (b) a polypeptide, or pharmaceutically acceptable salt thereof, which is a GLP-1R agonist polypeptide comprising an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 97% identity to cotadutide (HSQGTFTSD-X10-SEYLDSERARDFVAWLEAGG-acid, wherein X10=Lys[ε-γE-Palmitoyl], SEQ ID NO:
- 32);
- optionally wherein the GLP-1R agonist comprises an amino acid sequence having at least 65% identity to cotadutide.
(canceled)
31-35. (canceled)
(canceled)
39-41. (canceled)
43-47. (canceled)
(canceled)
Dependencies are inferred from the claim text.